| The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: the results of the HALT-MI study. | |
| | |
MedLine Citation:
|
PMID: 12383565 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: The purpose of this study was to determine whether Hu23F2G (LeukoArrest), an antibody to the CD11/CD18 integrin receptors, would reduce infarct size in patients undergoing primary angioplasty for an acute myocardial infarction. BACKGROUND: Reperfusion injury in acute myocardial infarction has been shown experimentally to be related to neutrophil accumulation. Inhibitors of the CD11/CD18 or CD18 integrin receptors have been shown to reduce infarct size in experimental models. METHODS: Patients within 6 h of onset of chest pain with ST-segment elevation were randomized to receive either 0.3 mg/kg or 1.0 mg/kg of Hu23F2G or placebo just before angioplasty of occluded arteries (Thrombolysis in Myocardial Infarction TIMI flow grade 0 or 1). The primary end point was infarct size as measured by sestamibi single-photon emission computed tomography (SPECT) scan five to nine days later. RESULTS: Four-hundred and twenty patients were enrolled and received a placebo or the study drug. The groups did not differ in baseline or angiographic characteristics or angioplasty results. Infarct size was 16%, 17.2% and 16.6%, for placebo, 0.3 mg/kg and 1.0 mg/kg, respectively, of the left ventricle (p = NS). No differences were evident in those patients with anterior myocardial infarction or those presenting within 2 h of onset of chest pain. Corrected TIMI frame count was also not different between groups. Clinical events at 30 days were very low, with a mortality of 0.8%, 1.4% and 3.3%, respectively. The drug was well tolerated, with a slight increase in minor infections in the high dose group. CONCLUSIONS: The results of this multicenter, double-blind, placebo-controlled, randomized clinical trial demonstrated that an antibody to CD11/CD18 leukocyte integrin receptor did not reduce infarct size in patients who underwent primary angioplasty. |
| | |
Authors:
|
David P Faxon; Raymond J Gibbons; Nicolas A F Chronos; Paul A Gurbel; Florence Sheehan; |
Related Documents
:
|
2526575 - Patient selection for percutaneous transluminal coronary angioplasty in acute myocardia... 10426875 - Primary stenting and glycoprotein iib/iiia inhibitors in acute myocardial infarction. 9263655 - An update on acute myocardial infarction from recent clinical trials. 15827315 - Abciximab as adjunctive therapy to reperfusion in acute st-segment elevation myocardial... 22398465 - Studies of isolated global brain ischaemia: i. overview of 'irreversible brain injury' ... 15055265 - Trends in cardiac surgery in israel, 1985-2002. |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Journal of the American College of Cardiology Volume: 40 ISSN: 0735-1097 ISO Abbreviation: J. Am. Coll. Cardiol. Publication Date: 2002 Oct |
Date Detail:
|
Created Date: 2002-10-17 Completed Date: 2002-11-04 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8301365 Medline TA: J Am Coll Cardiol Country: United States |
Other Details:
|
Languages: eng Pagination: 1199-204 Citation Subset: AIM; IM |
Affiliation:
|
Los Angeles County Medical Center and the University of Southern California School of Medicine, Los Angeles, California 60637, USA. dfaxon@medicine.bsd.uchicago.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angioplasty, Transluminal, Percutaneous Coronary Antibodies, Monoclonal / therapeutic use* Antigens, CD11 / immunology* Antigens, CD18 / immunology* Combined Modality Therapy Coronary Angiography Double-Blind Method Electrocardiography Female Humans Integrins / antagonists & inhibitors* Male Middle Aged Myocardial Infarction / diagnosis, immunology, mortality, therapy* Proportional Hazards Models Radiopharmaceuticals / diagnostic use Survival Analysis Technetium Tc 99m Sestamibi / diagnostic use Time Factors Tomography, Emission-Computed, Single-Photon Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Antigens, CD11; 0/Antigens, CD18; 0/HU23F2G; 0/Integrins; 0/Radiopharmaceuticals; 109581-73-9/Technetium Tc 99m Sestamibi |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Problems with intrapartum fetal heart rate monitoring interpretation and patient management.
Next Document: Coronary recanalization in anterior myocardial infarction: the open perforator hypothesis.